ATS Corporation Exits Auto and Bets Big on Nuclear and Radiopharma as New CEO Reshapes the Portfolio
Q4 Fiscal 2026 Earnings Call, May 28, 2026 — ATS Corporation pivots away from large-scale automotive work while doubling down on high-margin, high-consequence markets
The Transportation Exit Is More Than a Restructuring Line Item
The most consequential announcement from ATS Corporation's Q4 fiscal 2026 earnings call was not the headline revenue number — it was the formal decision to exit large-scale automotive manufacturing and dissolve transportation as a standalone reporting segment entirely. Interim CFO Anne Cybulski confirmed that the company is removing approximately $50 million of what she characterized as "dilutive revenues" and consolidating the related divisions, with the transportation vertical expected to disappear from ATS's segment reporting in the coming quarters. The company took $28.3 million in reorganization charges in Q4 related to closing out legacy projects, with a further $5 million in restructuring charges expected in Q1 fiscal 2027 as the operational consolidation is completed. Three facilities are currently held for sale, with proceeds earmarked to fund cash costs tied to the reorganization.
This is a deliberate portfolio cleaning exercise, not a distressed exit. CEO Doug Wright, who joined in January 2026, was direct about the rationale: large-scale automotive projects do not fit the long-term return profile ATS is targeting. The capabilities being freed up are being redeployed into what management describes as "specialized niche industrial applications" — citing as one example a partnership to break down end-of-life tires and recover reusable byproducts using ATS's engineering expertise, digital tools, and lifecycle support. It is an unusual application, but it illustrates the direction: complex, high-margin, technically differentiated work, not commodity automation.
Nuclear Is the Fastest-Growing Segment and a Likely M&A Target
Energy, which for ATS is primarily nuclear, posted the strongest growth of any segment in fiscal 2026, with order backlog up 40% year-on-year. This is perhaps the most underappreciated part of the ATS story. The company is active across CANDU reactor refurbishment and life-extension programs, as well as fuel systems, fuel handling, modular fabrication, and waste management for small modular reactor developers. Management noted that service revenues from refurbishment programs are expected to build as those projects advance, suggesting a recurring revenue tail that is not yet fully reflected in results.
Wright was unusually explicit about nuclear M&A. "Should there be an opportunity for us to deploy capital in that space, it would certainly be an area that we would consider very strongly," he said, adding that geographic positioning matters enormously in nuclear given its national-priority character. "If you're going to be in the U.S. market or the U.K. market, you have to have position there." For investors watching capital allocation, nuclear appears to be the highest-conviction organic and inorganic growth vector at ATS right now.
Radiopharma Is Replacing GLP-1 as the Life Sciences Growth Engine
Life Sciences remains the dominant segment at 55% of the $2 billion order backlog, but the composition is shifting. The GLP-1 auto-injector wave that drove exceptional bookings in fiscal 2025 has normalized, with that category now below the 20% of Life Sciences backlog and 10% of total backlog figures that management had previously cited. This was anticipated and is not a demand deterioration — it reflects the natural cadence of capacity build-out orders being worked through production. What is replacing it is radiopharma, which management described as building "strong momentum" as isotope supply expands and customers require specialized infrastructure to support complex, high-value programs at scale.
ATS recently introduced its Flex-Line platform, a sterile pharmaceutical production system that integrates key manufacturing steps into a single solution designed to accelerate market entry and reduce process complexity for radiopharma customers. The Life Sciences funnel entering fiscal 2027 is also notably broader: mail-order pharmacy, automated visual inspection, and lab automation are all cited as active areas, reducing the single-program concentration risk that made some investors nervous when GLP-1 dominated the conversation. Wright was confident on auto-injectors as a long-term delivery device across cardiovascular, autoimmune, and neurological indications beyond GLP-1, acknowledging lumpiness while defending the structural thesis.
Margin Expansion Guidance Is Conservative by Design
Management guided for 50 to 75 basis points of adjusted earnings from operations margin improvement for fiscal 2027 on an exit-rate basis, against a longer-term target of 15%. Gross margin in Q4 was 29.4%, up 36 basis points year-on-year, with the improvement driven by a higher contribution from services and spare parts — exactly the mix shift ATS is trying to engineer structurally. The 50 to 75 basis point guidance is explicitly described as non-linear and inclusive of reinvestment in growth areas like nuclear and radiopharma, so the gross restructuring benefit is partially obscured. Cybulski noted that "throughout fiscal '27, as we continue to pragmatically assess our strategic positions and market potential across our portfolio, there will likely be further opportunities for rationalization" — language that suggests the portfolio cleaning is not finished.
The recurring revenue base currently sits at roughly one-third of revenues. Getting that figure meaningfully higher is a central management priority, both because it is margin accretive and because it improves revenue predictability. Wright linked this explicitly to ATS's digital investments: "I believe strongly that our digital investments around things like digital twin, remote diagnostics, machine intelligence and the digital frontier that we're very focused on right now are really also a part of a broad service construct, and I think you'll see ATS in the future talking more about physical AI and automation intelligence as key drivers to our recurring revenue stack." That framing is worth watching — if ATS can convert digital capability into contracted service revenue, the multiple re-rating case becomes more credible.
Balance Sheet Is Ready for M&A; Framework Is Disciplined
Net debt to adjusted EBITDA ended Q4 at 2.8x, the fourth consecutive quarter of improvement and within the 2 to 3x target range. Operating cash flow in Q4 was $149.5 million, and non-cash working capital as a percentage of revenues improved to 12.1%, the third consecutive quarter of improvement and below the 15% long-term target. Wright described working capital discipline as a "hallmark" of ATS's operating performance and a "strong signal for process acumen," noting it is treated as a general management accountability, not a finance function exercise.
With leverage back in range, ATS is explicitly signaling readiness to deploy capital. Wright described the M&A pipeline as a "broad rainbow of valuations" across the spectrum, with some assets available below ATS's current trading multiple and others commanding premiums. The return hurdle is straightforward: exceed cost of capital over a three-plus year horizon, with higher returns preferred when competing uses of capital are available. Management confirmed that restructuring and M&A are independent workstreams and can proceed simultaneously — an important clarification for investors who might have assumed the portfolio cleanup needed to be completed before deal activity could resume.
Revenue Outlook Is Modest but the Explanation Is Credible
For fiscal 2027, ATS guided for "modest revenue growth" on a consolidated basis inclusive of the transportation step-down, with Q1 revenues expected in the range of $700 million to $740 million. Full-year organic growth excluding transportation was nearly 14% in fiscal 2026, and management's three-year CAGR on adjusted revenues and order bookings excluding transportation is approximately 12% — context that makes the fiscal 2027 moderation look like timing rather than structural deceleration. Book-to-bill for the trailing twelve months ended at 0.99x, reflecting deliberate execution against a large backlog rather than demand weakness. Wright's characterization of the pipeline as "very strong" and his explicit statement that "there's really no real drama in any of our end markets at this stage" was as direct a pushback on bear-case concerns as management offered on the call. Whether the modest revenue guide leaves room for upside will depend heavily on the pace of nuclear and radiopharma order conversion in the first half of the fiscal year.